Study investigates whether estrogen-containing therapy is associated with incident PCT, and whether the risk varies with estrogen type and route of administration.
The policy directs the FDA not to take action against specialty pharmacies that sell a half-dozen wellness peptides, including BPC-157, TB-500 and KPV.